Trial Details

Recruiting
Basic Information
Clinical ID c2136
Identifier ISRCTN12358813
Trial Title Asp-PSC: effect of aspirin on reducing cancer & improving outcomes in primary sclerosing cholangitis
Trial URL Visit Original Page
Study Information
Study Results

Yes
Conditions Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) Digestive System
Interventions Participants will be randomised using OpenClinica and assigned treatment via Sealed Envelope. Each treatment group will receive either 75 mg aspirin or a placebo tablet to take once a day, orally for 5 years. All participants will be screened and have the following visits: 1. Collection of aspirin/placebo visit 2. Month one phone call 3. 6 monthly visits for 5 years 4. End of treatment visit Endpoint data will be collected yearly after the end of treatment visit.
Participant Information
Sponsor Imperial College London
City -
Country/Region United Kingdom
Enrollment Criteria
Sex Requirement ALL
Age Requirement -
Study Design
Study Type Interventional
Phase PHASE3
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date 2033-07-31